Diagnostics News and Research

RSS

ChartMaxx achieves 2014 Edition Modular EHR ONC Health IT Certification

ChartMaxx, the enterprise content management (ECM) solution from Quest Diagnostics, has achieved 2014 Edition Modular EHR ONC Health IT Certification which supports both Stages 1 and 2 of the Meaningful Use (MU) program.

From Quest Diagnostics 12 Feb 2014

Experts to meet in Biovision's annual forum to discuss effects of disruptive innovation in healthcare

Biovision, the annual forum devoted to future-oriented research in life sciences, is launching this years’ registration campaign and its call for applications for innovative projects and companies. This year’s event will take place in Lyon, France, on June 5 and 6, 2014.

12 Feb 2014

Global decision-making has disastrous effect on human health

The organisation of political power within and between nations and citizens fails to protect the public's health, according to the findings of a new Commission from The Lancet and the University of Oslo, published today [Tuesday 11 February].

12 Feb 2014

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Eternity Healthcare Inc., a medical device and diagnostic company specializing in diabetes management, announced today that they are in development of a noninvasive sugar monitoring device using saliva instead of blood. The technology utilizes an ultra sensitive sugar monitor and an additional sensor for salivary amylase enzyme activity.

From Medtronic 11 Feb 2014

Covaris introduces truXTRAC High Throughput FFPE DNA Extraction & Purification Kit at 2014 AGBT

Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.

11 Feb 2014

EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

EKF, announces that its subsidiary company EKF Molecular Diagnostics is exhibiting its ground-breaking PointMan DNA-enrichment tech.

From EKF Diagnostics 11 Feb 2014

Rubicon Genomics introduces PicoPLEX DNA-seq Kits for use with Illumina NGS platforms

Rubicon Genomics, Inc. today announced the launch of its PicoPLEX DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX's outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

10 Feb 2014

Study: Investigational drug effective in reducing mucormycosis infections

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

7 Feb 2014

Highlights for first quarter of fiscal 2014 from MAXIMUS

MAXIMUS, a leading provider of government services worldwide, today reported financial results for its first quarter ended December 31, 2013.

6 Feb 2014

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a study published online in Circulation, the journal of the American Heart Association.

From Quest Diagnostics 5 Feb 2014

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms.

5 Feb 2014

Thermo Fisher Scientific acquires Life Technologies

Thermo Fisher Scientific, the world leader in serving science, today announced that it has completed its acquisition of Life Technologies Corporation (NASDAQ: LIFE) for $76.13 ($76.1311786) in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of $1.5 billion in net debt. The completion of the transaction follows the receipt of all required regulatory approvals.

4 Feb 2014

Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Antibiotic resistance is a consequence of antibiotic use. Bacteria adapt to the threat of antibiotics using mechanisms to overcome the drug. These bacteria, which we call resistant bacteria, then survive.

3 Feb 2014

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

31 Jan 2014

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

Thermo Fisher Scientific fourth quarter revenue increases 6% to $3.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2013.

30 Jan 2014

Researchers use natural DNA molecules to build DNA nanoarchitectures

A Rutgers-Camden scholar is performing research as part of a collaborative effort with Arizona State University to make significant advancements in nanotechnology.

30 Jan 2014

Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Myriad Genetics, Inc. today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients.

29 Jan 2014

Polymer Technology signs agreement to supply CardioChek PA test system to Workwell Consultants

Polymer Technology Systems, Inc., the U.S.-based manufacturer of the CardioChek® family of point-of-care diagnostic products and Whitmire Medical have announced the signing of an agreement to supply the CardioChek PA test system to Workwell Consultants as part of its ongoing effort to create healthier workplaces.

28 Jan 2014

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime, Inc. and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.